GeoVax Labs, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer. GeoVax’s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers. Through the Company’s novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine. The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
Ticker:
GOVX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
HIV Vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chairman, President & CEO
GeoVax Labs, Inc